Literature DB >> 21564401

Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital.

Cui Hua Liu1, Nan Yang, Qi Wang, Yong Liang Hu, Ling Li, Guang Yu Zhang, Baoli Zhu.   

Abstract

BACKGROUND AND
OBJECTIVE: The rapid increase in the number of multi-drug-resistant tuberculosis (MDR-TB) cases worldwide emphasizes the importance of rational use of key important life-saving second-line anti-TB drugs such as fluoroquinolones. In order to provide information for better case management, so as to minimize the further spread of extensively drug-resistant TB, a retrospective study was performed to assess the risk factors associated with fluoroquinolone resistance among TB patients attending the 309 Hospital in Beijing, China.
METHODS: Drug susceptibility testing results and clinical data for hospitalized TB patients for the period 2000-2010 were analysed. Univariate and multivariate analyses were used to determine the risk factors associated with fluoroquinolone-resistant TB.
RESULTS: From July 2000 to July 2010, ofloxacin resistance was observed in 306 of 3546 (8.6%) hospitalized TB patients who were tested. The independent risk factors associated with fluoroquinolone-resistant TB were being single (adjusted OR 1.65), being a migrant living in Beijing (adjusted OR 2.15), being a migrant from another area (adjusted OR 5.07), being a patient who was retreated (adjusted OR 2.84), exposure to fluoroquinolones (adjusted OR 2.73), having COPD (adjusted OR 3.53), having COPD with known exposure to fluoroquinolones (adjusted OR 2.47), having MDR-TB (adjusted OR 1.67), and having poly-resistant TB (adjusted OR 2.34).
CONCLUSIONS: These findings suggest that in high-risk populations continuous surveillance of fluoroquinolone resistance should be maintained. In addition, programs should be implemented for the management of patients with MDR-TB and more complicated TB, so as to minimize the further spread of fluoroquinolone resistance and extensively drug-resistant TB.
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21564401     DOI: 10.1111/j.1440-1843.2011.01990.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

Review 1.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

2.  Year in review 2011: respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  José M Porcel; Chi Chiu Leung; Marcos I Restrepo; Pyng Lee
Journal:  Respirology       Date:  2012-04       Impact factor: 6.424

3.  Increased cytokines response in patients with tuberculosis complicated with chronic obstructive pulmonary disease.

Authors:  Shenjie Tang; Haiyan Cui; Lan Yao; Xiaohui Hao; Yun Shen; Lin Fan; Hua Sun; Zhanjun Zhang; Jian An Huang
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

4.  Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China.

Authors:  Xiao-Chun He; Ning-Ning Tao; Yao Liu; Xian-Xin Zhang; Huai-Chen Li
Journal:  BMC Infect Dis       Date:  2017-08-09       Impact factor: 3.090

5.  Low Levels of Extensively Drug-resistant Tuberculosis among Multidrug Resistant Tuberculosis Isolates and Their Relationship to Risk Factors: Surveillance in Tehran, Iran; 2006 to 2014.

Authors:  Alireza Hadizadeh Tasbiti; Shamsi Yari; Mostafa Ghanei; Mohammad Ali Shokrgozar; Abolfazl Fateh; Ahmadreza Bahrmand
Journal:  Osong Public Health Res Perspect       Date:  2017-04-30

6.  Multidrug-Resistant Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease in China.

Authors:  Jiang-Nan Zhao; Xian-Xin Zhang; Xiao-Chun He; Guo-Ru Yang; Xiao-Qi Zhang; Wen-Gen Xin; Huai-Chen Li
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.